Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: Empagliflozin in Pediatric NAFLD
NCT06355310Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in non-alcoholic fatty liver disease (NAFLD). Started Apr 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06355310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355310.